articleTop 1% cited
Prognostic markers in triple‐negative breast cancer
Cancer · 2006 · Vol. 109(1) · pp. 25–32
Emad A. Rakha✉(University of Nottingham)Maysa E. El‐Sayed(University of Nottingham)Andrew R. Green(University of Nottingham)Andrew H.S. Lee(University of Nottingham)J.F.R. Robertson(National Health Service)Ian O. Ellis(University of Nottingham)
Abstract
The authors concluded that assessment of androgen receptor and basal phenotype, in addition to the established pathologic variables, mainly lymph node status and tumor size, can be used to select high-risk and low-risk patients at the time of primary surgery and can provide valuable information on treatment options in these triple-negative tumors.
HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer-related Molecular PathwaysMedicineTriple-negative breast cancerCancerBreast cancerOncologyTriple negativeInternal medicine
MeSH terms
AdultAgedBreast NeoplasmsFemaleFollow-Up StudiesHumansImmunohistochemistryMiddle AgedPhenotypePrognosisReceptors, AndrogenReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorCadherins
Citations
1,276
FWCI
27.29
field-weighted impact
References
50
Percentile
100%
vs. same field & year
Citations per year
Cited by
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
Clinical Cancer Research · 2008 · 1,187 citations
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
Breast Cancer Research and Treatment · 2007 · 319 citations
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Breast Cancer Research and Treatment · 2008 · 396 citations
Mechanisms of immune evasion in breast cancer
BMC Cancer · 2018 · 311 citations
Triple negative breast cancer: unmet medical needs
Breast Cancer Research and Treatment · 2010 · 325 citations
Role of epidermal growth factor receptor in breast cancer
Breast Cancer Research and Treatment · 2012 · 786 citations
References
Expression of luminal and basal cytokeratins in human breast carcinoma
The Journal of Pathology · 2004 · 597 citations
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Cancer · 1989 · 2,286 citations
The Nottingham prognostic index in primary breast cancer
Breast Cancer Research and Treatment · 1992 · 1,067 citations
High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses
International Journal of Cancer · 2005 · 611 citations
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Nature Medicine · 1998 · 4,127 citations
Molecular portraits of human breast tumours
Nature · 2000 · 16,173 citations
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proceedings of the National Academy of Sciences · 2001 · 10,888 citations
Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome
American Journal Of Pathology · 2002 · 563 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
